Stormoen, Dag Rune
Rohrberg, Kristoffer Staal
Mouw, Kent William
Ørum, Katrine
Szallasi, Zoltan
Rossing, Maria
Bagger, Frederik Otzen
Pappot, Helle
Funding for this research was provided by:
Copenhagen University
Article History
Received: 13 May 2024
Accepted: 14 June 2024
First Online: 8 July 2024
Declarations
:
: D.R.S. received educational and research funding from Pfizer and Merck Serono for other projects unrelated to this study, served on advisory boards for Merck Sharp and Dome (MSD), Bristol Meyers Squibb and Johnson and Johnson, unrelated to this study; K.S.R: No COI to report; K.W.M: Advisory/consulting work for EMD Serono, Pfizer, UroGen, and Riva Therapeutics; has received research support from Pfizer and Novo Ventures; has equity in Riva Therapeutics; has received writing/editor fees from UpToDate; has received speaking fees from OncLive; and is a co-inventor listed on an institutional patent application for analysis of mutational signatures of DNA repair deficiency; K.Ø: No COI to report, F.O.B: received personal fees from AstraZeneca, and served as scientific advisor through ownership of FOBinf for Immunitrack, Hervolution and Aida Oncology unrelated to this work, Z.S: Research funding from Lantern Pharma Inc; M.R: received personal fees from AstraZeneca and MSD and served on advisory board of MSD outside the submitted work.; H.P: Research funding from Pfizer and Merck unrelated to this study.